TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit
12 mai 2022 09h00 HE
|
Gb Sciences
LAS VEGAS, May 12, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and...
TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference
05 mai 2022 09h30 HE
|
Gb Sciences
LAS VEGAS, May 05, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and...
FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies
02 mai 2022 09h00 HE
|
Gb Sciences
LAS VEGAS, May 02, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, announces that FHI Clinical Inc. will...
Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge
12 avr. 2022 09h00 HE
|
Gb Sciences
LAS VEGAS, April 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, has selected the University of Lethbridge...
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article
29 mars 2022 08h00 HE
|
Gb Sciences
LAS VEGAS, March 29, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired, biopharmaceutical research and development company, announces that their...
UPDATE: Gb Sciences Issues Shareholder Letter
16 mars 2022 15h01 HE
|
Gb Sciences
LAS VEGAS, March 16, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, today issued a letter to...
Gb Sciences Issues Summary Shareholder Letter
15 mars 2022 07h00 HE
|
Gb Sciences
LAS VEGAS, March 15, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, today issued a letter to...
Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis
01 mars 2022 07h00 HE
|
Gb Sciences
LAS VEGAS, March 01, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has been issued a new patent today by the...
Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment
01 févr. 2022 07h00 HE
|
Gb Sciences
LAS VEGAS, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Following the promising study on cannabinoids and COVID-19 published by Oregon State University, Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-based...
Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility
11 janv. 2022 07h54 HE
|
Gb Sciences
LAS VEGAS, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has closed the sale of its last...